Immune to Cancer: The CRI Blog
-
Merck’s PD-1 Drug Outperforms Ipilimumab for Treatment of Advanced Melanoma
Data from a phase III trial indicate that Keytruda stands ready to become standard-of-care for advanced melanoma.
-
Five Myths about Clinical Trials that Just Won’t Go Away
Curious about what happens when you enroll in a clinical trial? Hear firsthand about one woman's experience.
-
Phase 3 Trial of Nivolumab Shows Survival Advantage in Lung Cancer
The results of a phase III trial are clear: the PD-1 checkpoint inhibitor nivolumab improves survival for…
-
Making Pancreatic Cancer a Target for Immunotherapy
Researchers show that pancreatic cancer, long known to resist immunotherapy, can be made immunogenic after all.